tradingkey.logo
tradingkey.logo
Search

NewGenIvf Group Ltd

NIVF
Add to Watchlist
0.900USD
-0.071-7.29%
Close 05/15, 16:00ETQuotes delayed by 15 min
511.69KMarket Cap
0.00P/E TTM

NewGenIvf Group Ltd

0.900
-0.071-7.29%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-7.29%

5 Days

-25.62%

1 Month

-63.86%

6 Months

-96.04%

Year to Date

-89.13%

1 Year

-99.90%

TradingKey Stock Score of NewGenIvf Group Ltd

Currency: USD Updated: 2026-05-15

Key Insights

NewGenIvf Group Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered undervalued, ranking 63 out of 74 in the Healthcare Providers & Services industry.Institutional ownership is relatively high.Over the past month, multiple analysts have rated it as , with the highest price target at 900.00.In the medium term, the stock price is expected to trend down.

NewGenIvf Group Ltd's Score

Industry at a Glance

Industry Ranking
63 / 74
Overall Ranking
528 / 4482
Industry
Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

NewGenIvf Group Ltd Highlights

StrengthsRisks
NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.73M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.73M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.51K shares, increasing 45.71% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.30.

Analyst Rating

Based on 0 analysts
--
Current Rating
900.000
Target Price
+92607.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

NewGenIvf Group Ltd News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

NewGenIvf Group Ltd Info

NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
Ticker SymbolNIVF
CompanyNewGenIvf Group Ltd
CEOWing Fung (Siu)
Websitehttps://newgenivf.com/
KeyAI